BIOPHYTIS

Biophytis (ALBPS.PA) trades at €0.04 with a 1.19% rise, offering insights into its age‑related therapies and current trials in sarcopenia, DMD, and macular degeneration.

Biophytis lingers near zero: a fragile biotech stock with a 28% drop, €0.03 price, €11.7M cap, and opaque pipeline. Investors weigh high risk, low reward amid uncertain clinical progress.

Biophytis stock drops 15% to €0.03, falling below its 200‑day average amid volatile biotech market; explore the firm’s anti‑aging and rare‑disease pipeline.